https://mindmedicinelaw.com/briefing/psychedelic-trials-methodology-faces-critical-review-20260609-11436The Psychedelic Journalen2026-06-09T15:03:58.478710+00:00Psychedelic Trials' Methodology Faces Critical Reviewpsychedelic trials, methodology scrutiny, clinical research, placebo controls, trial design, regulatory standards, psilocybin, MDMA, FDA approval, scientific integrityhttps://mindmedicinelaw.com/briefing/chicago-va-s-psilocybin-therapy-for-veterans-with-ptsd-20260609-11437The Psychedelic Journalen2026-06-09T15:03:46.616586+00:00Chicago VA's Psilocybin Therapy for Veterans with PTSDpsilocybin therapy, PTSD treatment, veterans mental health, psychedelic research, Chicago VA Hospital, psychiatric protocols, mental health care, clinical trials, psychedelic therapies, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/neuroinflammation-s-impact-on-treatment-resistant-depression-20260608-11510The Psychedelic Journalen2026-06-09T22:03:15.367776+00:00Neuroinflammation's Impact on Treatment-Resistant Depressiontreatment-resistant depression, neuroinflammation, personalized medicine, inflammatory markers, next-generation antidepressants, blood-brain barrier, major depressive disorder, immune system, mental health, biological subtypeshttps://mindmedicinelaw.com/briefing/meta-analysis-psychedelics-for-ptsd-treatment-20260608-11509The Psychedelic Journalen2026-06-09T22:02:58.037978+00:00Meta-Analysis: Psychedelics for PTSD TreatmentMDMA, PTSD, psychedelic-assisted psychotherapy, ketamine, cannabidiol, systematic review, meta-analysis, randomized controlled trials, efficacy, safetyhttps://mindmedicinelaw.com/briefing/fda-s-comp360-approval-path-implications-for-psychedelics-20260608-11286The Psychedelic Journalen2026-06-08T22:04:13.815212+00:00FDA's COMP360 Approval Path: Implications for PsychedelicsFDA approval, COMP360, REMS, psilocybin therapy, psychedelic industry, regulatory process, investor implications, clinical trials, risk management, psychedelic researchhttps://mindmedicinelaw.com/briefing/french-study-examines-psilocybin-from-red-light-holland-20260608-11131The Psychedelic Journalen2026-06-08T15:04:30.772947+00:00French Study Examines Psilocybin from Red Light Hollandpsilocybin research, French brain study, Red Light Holland, psychedelic trials, commercial suppliers, international research, brain effects, policy implications, neuroscience, clinical applicationshttps://mindmedicinelaw.com/briefing/psychedelic-therapy-pilot-shows-promise-for-depression-20260608-11130The Psychedelic Journalen2026-06-08T15:04:21.191708+00:00Psychedelic Therapy Pilot Shows Promise for Depressionpsychedelic therapy, clinical depression, pilot trial, mental health treatment, psilocybin, serotonin receptors, treatment protocols, psychiatric research, safety and efficacy, regulatory considerationhttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-in-adhd-neuroplasticity-insights-20260605-11119The Psychedelic Journalen2026-06-08T15:04:49.416717+00:00Psilocybin's Potential in ADHD: Neuroplasticity Insightspsilocybin, ADHD, neuroplasticity, prenatal stress, clinical trials, psychedelic research, mental health, neuroscience, therapeutic potentialhttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-in-social-anxiety-disorder-trials-20260604-11496The Psychedelic Journalen2026-06-09T22:03:07.065122+00:00MDMA-Assisted Therapy in Social Anxiety Disorder Trialsmdma-assisted therapy, social anxiety disorder, clinical trials, psychedelics, mental health, treatment efficacy, neuroscience, public health, regulatory considerations, adverse eventshttps://mindmedicinelaw.com/briefing/therapeutic-alliance-in-psilocybin-therapy-for-depression-20260604-11055The Psychedelic Journalen2026-06-08T15:04:41.054969+00:00Therapeutic Alliance in Psilocybin Therapy for Depressiontherapeutic alliance, psilocybin therapy, treatment-resistant depression, ego dissolution, psychedelic therapy, clinical outcomes, psychotherapy integration, depression treatment, mental health, clinical trials